How Do MRI Findings Influence Rectal Cancer Management?

Abstract

Treatment of rectal cancer is currently guided by the need to reduce local recurrence, improve survival, reduce treatment-related toxicity, and improve the patient's quality of life (QoL). Magnetic resonance imaging (MRI) scan is now the imaging modality of choice for rectal cancer. However, the role of MRI in rectal cancer has transformed beyond describing the local stage of cancer to becoming a tool to predict the prognosis of a patient by its ability to detect features associated with a high risk of recurrence and poor survival. This greatly helps the multidisciplinary team (MDT) responsible for treating patients with rectal cancer to stratify them based on the potential for recurrence and decide on the need for and type of preoperative treatment to be offered. MRI also has the ability to assess the response to such treatments, based on which the MDT can tailor the subsequent treatment. This has the potential to spare the patient from unnecessary treatment, thus improving the QoL. MRI provides a roadmap to the surgeon while planning the surgery. In this review, we give a brief overview of the current management strategies for rectal cancer and highlight the role of MRI in the decision-making process.

Keywords

magnetic resonance imaging - rectal cancer - multidisciplinary team - neoadjuvant treatment

Publication History

Article published online:
10 January 2025

• References

• 1 Bray F, Laversanne M, Sung H. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74 (03) 229-263
• 2 Burton S, Brown G, Daniels IR, Norman AR, Mason B, Cunningham D. Royal Marsden Hospital, Colorectal Cancer Network. MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive circumferential margins?. Br J Cancer 2006; 94 (03) 351-357
• 3 Palmer G, Martling A, Cedermark B, Holm T. Preoperative tumour staging with multidisciplinary team assessment improves the outcome in locally advanced primary rectal cancer. Colorectal Dis 2011; 13 (12) 1361-1369
• 4 Glynne-Jones R, Wyrwicz L, Tiret E. et al; ESMO Guidelines Committee. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28 (suppl_4): iv22-iv40
• 5 National Comprehensive Cancer Network. National Comprehensive Cancer Network Guidelines, version 4.2024. Rectal cancer. Accessed September 18, 2024 at: https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf
• 6 Brown G, Davies S, Williams GT. et al. Effectiveness of preoperative staging in rectal cancer: digital rectal examination, endoluminal ultrasound or magnetic resonance imaging?. Br J Cancer 2004; 91 (01) 23-29
• 7 Phillips RK, Hittinger R, Blesovsky L, Fry JS, Fielding LP. Local recurrence following “curative” surgery for large bowel cancer: II. The rectum and rectosigmoid. Br J Surg 1984; 71 (01) 17-20
• 8 McDermott FT, Hughes ES, Pihl EA, Milne BJ. Changing survival prospects in carcinoma of the rectum. Br J Surg 1980; 67 (11) 775-780
• 9 Pollett WG, Nicholls RJ. The relationship between the extent of distal clearance and survival and local recurrence rates after curative anterior resection for carcinoma of the rectum. Ann Surg 1983; 198 (02) 159-163
• 10 Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986; 1 (8496): 1479-1482
• 11 Sauer R, Becker H, Hohenberger W. et al; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351 (17) 1731-1740
• 12 Kapiteijn E, Marijnen CA, Nagtegaal ID. et al; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345 (09) 638-646
• 13 Bosset JF, Collette L, Calais G. et al; EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355 (11) 1114-1123
• 14 Thomas PR, Lindblad AS. Adjuvant postoperative radiotherapy and chemotherapy in rectal carcinoma: a review of the Gastrointestinal Tumor Study Group experience. Radiother Oncol 1988; 13 (04) 245-252
• 15 Ngan SY, Burmeister B, Fisher RJ. et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012; 30 (31) 3827-3833
• 16 Erlandsson J, Holm T, Pettersson D. et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol 2017; 18 (03) 336-346
• 17 Bahadoer RR, Dijkstra EA, van Etten B. et al; RAPIDO collaborative investigators. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22 (01) 29-42
• 18 Conroy T, Bosset JF, Etienne PL. et al; Unicancer Gastrointestinal Group and Partenariat de Recherche en Oncologie Digestive (PRODIGE) Group. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22 (05) 702-715
• 19 Garcia-Aguilar J, Patil S, Gollub MJ. et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol 2022; 40 (23) 2546-2556
• 20 Cawthorn SJ, Parums DV, Gibbs NM. et al. Extent of mesorectal spread and involvement of lateral resection margin as prognostic factors after surgery for rectal cancer. Lancet 1990; 335 (8697): 1055-1059
• 21 Merkel S, Mansmann U, Siassi M, Papadopoulos T, Hohenberger W, Hermanek P. The prognostic inhomogeneity in pT3 rectal carcinomas. Int J Colorectal Dis 2001; 16 (05) 298-304
• 22 Merkel S, Weber K, Schellerer V. et al. Prognostic subdivision of ypT3 rectal tumours according to extension beyond the muscularis propria. Br J Surg 2014; 101 (05) 566-572
• 23 MERCURY Study Group. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology 2007; 243 (01) 132-139
• 24 Taylor FG, Quirke P, Heald RJ. et al; MERCURY study group. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Ann Surg 2011; 253 (04) 711-719
• 25 Kennedy ED, Simunovic M, Jhaveri K. et al. Safety and feasibility of using magnetic resonance imaging criteria to identify patients with “good prognosis” rectal cancer eligible for primary surgery: the phase 2 nonrandomized quicksilver clinical trial. JAMA Oncol 2019; 5 (07) 961-966
• 26 Hermanek P, Merkel S, Fietkau R, Rödel C, Hohenberger W. Regional lymph node metastasis and locoregional recurrence of rectal cancer in the era of TNM surgery. Implications for treatment decisions. Int J Colorectal Dis 2010; 25: 359368
• 27 Li XT, Sun YS, Tang L, Cao K, Zhang XY. Evaluating local lymph node metastasis with magnetic resonance imaging, endoluminal ultrasound and computed tomography in rectal cancer: a meta-analysis. Colorectal Dis 2015; 17 (06) O129-O135
• 28 Kim JH, Beets GL, Kim MJ, Kessels AG, Beets-Tan RG. High-resolution MR imaging for nodal staging in rectal cancer: are there any criteria in addition to the size?. Eur J Radiol 2004; 52 (01) 78-83
• 29 Beets-Tan RGH, Lambregts DMJ, Maas M. et al. Magnetic resonance imaging for clinical management of rectal cancer: updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol 2018; 28 (04) 1465-1475
• 30 Smith N, Brown G. Preoperative staging of rectal cancer. Acta Oncol 2008; 47 (01) 20-31
• 31 Brown G, Radcliffe AG, Newcombe RG, Dallimore NS, Bourne MW, Williams GT. Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging. Br J Surg 2003; 90 (03) 355-364
• 32 Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 1986; 2 (8514): 996-999
• 33 Birbeck KF, Macklin CP, Tiffin NJ. et al. Rates of circumferential resection margin involvement vary between surgeons and predict outcomes in rectal cancer surgery. Ann Surg 2002; 235 (04) 449-457
• 34 Wibe A, Rendedal PR, Svensson E. et al. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg 2002; 89 (03) 327-334
• 35 Hall NR, Finan PJ, al-Jaberi T. et al. Circumferential margin involvement after mesorectal excision of rectal cancer with curative intent. Predictor of survival but not local recurrence?. Dis Colon Rectum 1998; 41 (08) 979-983
• 36 Beets-Tan RG, Beets GL, Vliegen RF. et al. Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery. Lancet 2001; 357 (9255): 497-504
• 37 MERCURY Study Group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ 2006; 333 (7572): 779
• 38 Kim SH, Lee JM, Park HS, Eun HW, Han JK, Choi BI. Accuracy of MRI for predicting the circumferential resection margin, mesorectal fascia invasion, and tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer. J Magn Reson Imaging 2009; 29 (05) 1093-1101
• 39 Al-Sukhni E, Milot L, Fruitman M. et al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. Ann Surg Oncol 2012; 19 (07) 2212-2223
• 40 Taylor FG, Quirke P, Heald RJ. et al; Magnetic Resonance Imaging in Rectal Cancer European Equivalence Study Study Group. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. J Clin Oncol 2014; 32 (01) 34-43
• 41 Martling A, Holm T, Bremmer S, Lindholm J, Cedermark B, Blomqvist L. Prognostic value of preoperative magnetic resonance imaging of the pelvis in rectal cancer. Br J Surg 2003; 90 (11) 1422-1428
• 42 Horn A, Dahl O, Morild I. The role of venous and neural invasion on survival in rectal adenocarcinoma. Dis Colon Rectum 1990; 33 (07) 598-601
• 43 Rich T, Gunderson LL, Lew R, Galdibini JJ, Cohen AM, Donaldson G. Patterns of recurrence of rectal cancer after potentially curative surgery. Cancer 1983; 52 (07) 1317-1329
• 44 Krasna MJ, Flancbaum L, Cody RP, Shneibaum S, Ben Ari G. Vascular and neural invasion in colorectal carcinoma. Incidence and prognostic significance. Cancer 1988; 61 (05) 1018-1023
• 45 Smith NJ, Shihab O, Arnaout A, Swift RI, Brown G. MRI for detection of extramural vascular invasion in rectal cancer. AJR Am J Roentgenol 2008; 191 (05) 1517-1522
• 46 Jhaveri KS, Hosseini-Nik H, Thipphavong S. et al. MRI detection of extramural venous invasion in rectal cancer: correlation with histopathology using elastin stain. AJR Am J Roentgenol 2016; 206 (04) 747-755
• 47 Patel UB, Brown G, Rutten H. et al. Comparison of magnetic resonance imaging and histopathological response to chemoradiotherapy in locally advanced rectal cancer. Ann Surg Oncol 2012; 19 (09) 2842-2852
• 48 Chand M, Evans J, Swift RI. et al. The prognostic significance of postchemoradiotherapy high-resolution MRI and histopathology detected extramural venous invasion in rectal cancer. Ann Surg 2015; 261 (03) 473-479
• 49 Sohn B, Lim JS, Kim H. et al. MRI-detected extramural vascular invasion is an independent prognostic factor for synchronous metastasis in patients with rectal cancer. Eur Radiol 2015; 25 (05) 1347-1355
• 50 Smith NJ, Barbachano Y, Norman AR, Swift RI, Abulafi AM, Brown G. Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer. Br J Surg 2008; 95 (02) 229-236
• 51 Tan JJ, Carten RV, Babiker A, Abulafi M, Lord AC, Brown G. Prognostic importance of MRI-detected extramural venous invasion in rectal cancer: a literature review and systematic meta-analysis. Int J Radiat Oncol Biol Phys 2021; 111 (02) 385-394
• 52 Liu L, Liu M, Yang Z, He W, Wang Z, Jin E. Correlation of MRI-detected extramural vascular invasion with regional lymph node metastasis in rectal cancer. Clin Imaging 2016; 40 (03) 456-460
• 53 Bugg WG, Andreou AK, Biswas D, Toms AP, Williams SM. The prognostic significance of MRI-detected extramural venous invasion in rectal carcinoma. Clin Radiol 2014; 69 (06) 619-623
• 54 Siddiqui MRS, Simillis C, Hunter C. et al. A meta-analysis comparing the risk of metastases in patients with rectal cancer and MRI-detected extramural vascular invasion (mrEMVI) vs mrEMVI-negative cases. Br J Cancer 2017; 116 (12) 1513-1519
• 55 Lord AC, D'Souza N, Shaw A. et al. MRI-diagnosed tumor deposits and EMVI status have superior prognostic accuracy to current clinical TNM staging in rectal cancer. Ann Surg 2022; 276 (02) 334-344
• 56 Chand M, Bhangu A, Wotherspoon A. et al. EMVI-positive stage II rectal cancer has similar clinical outcomes as stage III disease following pre-operative chemoradiotherapy. Ann Oncol 2014; 25 (04) 858-863
• 57 Chand M, Swift RI, Tekkis PP, Chau I, Brown G. Extramural venous invasion is a potential imaging predictive biomarker of neoadjuvant treatment in rectal cancer. Br J Cancer 2014; 110 (01) 19-25
• 58 Schaap DP, Voogt ELK, Burger JWA. et al. Prognostic implications of MRI-detected EMVI and tumor deposits and their response to neoadjuvant therapy in cT3 and cT4 rectal cancer. Int J Radiat Oncol Biol Phys 2021; 111 (03) 816-825
• 59 Nagtegaal ID, Knijn N, Hugen N. et al. Tumor deposits in colorectal cancer: improving the value of modern staging: a systematic review and meta-analysis. J Clin Oncol 2017; 35 (10) 1119-1127
• 60 Lord AC, D'Souza N, Pucher PH. et al. Significance of extranodal tumour deposits in colorectal cancer: a systematic review and meta-analysis. Eur J Cancer 2017; 82: 92-102
• 61 Sugihara K, Kobayashi H, Kato T. et al. Indication and benefit of pelvic sidewall dissection for rectal cancer. Dis Colon Rectum 2006; 49 (11) 1663-1672
• 62 Hazen SJA, Sluckin TC, Konishi T, Kusters M. Lateral lymph node dissection in rectal cancer: state of the art review. Eur J Surg Oncol 2022; 48 (11) 2315-2322
• 63 Iversen H, Martling A, Johansson H, Nilsson PJ, Holm T. Pelvic local recurrence from colorectal cancer: surgical challenge with changing preconditions. Colorectal Dis 2018; 20 (05) 399-406
• 64 Kim TH, Jeong SY, Choi DH. et al. Lateral lymph node metastasis is a major cause of locoregional recurrence in rectal cancer treated with preoperative chemoradiotherapy and curative resection. Ann Surg Oncol 2008; 15 (03) 729-737
• 65 Ogura A, Konishi T, Cunningham C. et al; Lateral Node Study Consortium. Neoadjuvant (chemo)radiotherapy with total mesorectal excision only is not sufficient to prevent lateral local recurrence in enlarged nodes: results of the multicenter lateral node study of patients with low cT3/4 rectal cancer. J Clin Oncol 2019; 37 (01) 33-43
• 66 Schaap DP, Boogerd LSF, Konishi T. et al; Lateral Node Study Consortium. Rectal cancer lateral lymph nodes: multicentre study of the impact of obturator and internal iliac nodes on oncological outcomes. Br J Surg 2021; 108 (02) 205-213
• 67 Sluckin TC, Couwenberg AM, Lambregts DMJ. et al. Lateral lymph nodes in rectal cancer: do we all think the same? A review of multidisciplinary obstacles and treatment recommendations. Clin Colorectal Cancer 2022; 21 (02) 80-88
• 68 Lambregts DMJ, Bogveradze N, Blomqvist LK. et al. Current controversies in TNM for the radiological staging of rectal cancer and how to deal with them: results of a global online survey and multidisciplinary expert consensus. Eur Radiol 2022; 32 (07) 4991-5003
• 69 Ogura A, Konishi T, Beets GL. et al; Lateral Node Study Consortium. Lateral nodal features on restaging magnetic resonance imaging associated with lateral local recurrence in low rectal cancer after neoadjuvant chemoradiotherapy or radiotherapy. JAMA Surg 2019; 154 (09) e192172
• 70 Lambregts DM, Vandecaveye V, Barbaro B. et al. Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study. Ann Surg Oncol 2011; 18 (08) 2224-2231
• 71 Lambregts DMJ, Delli Pizzi A, Lahaye MJ. et al. A pattern-based approach combining tumor morphology on MRI with distinct signal patterns on diffusion-weighted imaging to assess response of rectal tumors after chemoradiotherapy. Dis Colon Rectum 2018; 61 (03) 328-337
• 72 Thompson HM, Omer DM, Lin S. et al; OPRA Consortium. Organ preservation and survival by clinical response grade in patients with rectal cancer treated with total neoadjuvant therapy: a secondary analysis of the OPRA randomized clinical trial. JAMA Netw Open 2024; 7 (01) e2350903
• 73 Patel UB, Taylor F, Blomqvist L. et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol 2011; 29 (28) 3753-3760
• 74 Patel UB, Blomqvist LK, Taylor F. et al. MRI after treatment of locally advanced rectal cancer: how to report tumor response: the MERCURY experience. AJR Am J Roentgenol 2012; 199 (04) W486-95
• 75 Chandramohan A, Siddiqi UM, Mittal R. et al. Diffusion weighted imaging improves diagnostic ability of MRI for determining complete response to neoadjuvant therapy in locally advanced rectal cancer. Eur J Radiol Open 2020; 7: 100223
• 76 Yu SKT, Tait D, Chau I, Brown G. MRI predictive factors for tumor response in rectal cancer following neoadjuvant chemoradiation therapy: implications for induction chemotherapy?. Int J Radiat Oncol Biol Phys 2013; 87 (03) 505-511
• 77 Schrag D, Shi Q, Weiser MR. et al. Preoperative treatment of locally advanced rectal cancer. N Engl J Med 2023; 389 (04) 322-334
• 78 Scott AJ, Kennedy EB, Berlin J. et al. Management of locally advanced rectal cancer: ASCO guideline. J Clin Oncol 2024; 42 (28) 3355-3375
• 79 Martens MH, Maas M, Heijnen LA. et al. Long-term outcome of an organ preservation program after neoadjuvant treatment for rectal cancer. J Natl Cancer Inst 2016; 108 (12) djw171
• 80 Bercz A, Park BK, Pappou E. et al. Organ preservation after neoadjuvant long-course chemoradiotherapy versus short-course radiotherapy. Ann Oncol 2024; 35 (11) 1003-1014
• 81 van der Valk MJM, Hilling DE, Bastiaannet E. et al; IWWD Consortium. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet 2018; 391 (10139): 2537-2545
• 82 Verheij FS, Omer DM, Williams H. et al. Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA trial. J Clin Oncol 2024; 42 (05) 500-506
• 83 Marr R, Birbeck K, Garvican J. et al. The modern abdominoperineal excision: the next challenge after total mesorectal excision. Ann Surg 2005; 242 (01) 74-82
• 84 Nagtegaal ID, van de Velde CJH, Marijnen CAM, van Krieken JHJM, Quirke P. Dutch Colorectal Cancer Group, Pathology Review Committee. Low rectal cancer: a call for a change of approach in abdominoperineal resection. J Clin Oncol 2005; 23 (36) 9257-9264
• 85 Faerden AE, Naimy N, Wiik P. et al. Total mesorectal excision for rectal cancer: difference in outcome for low and high rectal cancer. Dis Colon Rectum 2005; 48 (12) 2224-2231
• 86 Brown G, Kirkham A, Williams GT. et al. High-resolution MRI of the anatomy important in total mesorectal excision of the rectum. AJR Am J Roentgenol 2004; 182 (02) 431-439
• 87 Salerno GV, Daniels IR, Moran BJ, Heald RJ, Thomas K, Brown G. Magnetic resonance imaging prediction of an involved surgical resection margin in low rectal cancer. Dis Colon Rectum 2009; 52 (04) 632-639
• 88 Shihab OC, Moran BJ, Heald RJ, Quirke P, Brown G. MRI staging of low rectal cancer. Eur Radiol 2009; 19 (03) 643-650
• 89 Battersby NJ, How P, Moran B. et al; MERCURY II Study Group. Prospective validation of a low rectal cancer magnetic resonance imaging staging system and development of a local recurrence risk stratification model: the MERCURY II study. Ann Surg 2016; 263 (04) 751-760
• 90 Beyond TME. Beyond TME Collaborative. Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. Br J Surg 2013; 100 (08) E1-E33
• 91 Georgiou PA, Tekkis PP, Constantinides VA. et al. Diagnostic accuracy and value of magnetic resonance imaging (MRI) in planning exenterative pelvic surgery for advanced colorectal cancer. Eur J Cancer 2013; 49 (01) 72-81
• 92 Brown WE, Koh CE, Badgery-Parker T, Solomon MJ. Validation of MRI and surgical decision making to predict a complete resection in pelvic exenteration for recurrent rectal cancer. Dis Colon Rectum 2017; 60 (02) 144-151
• 93 Stelzner S, Kittner T, Schneider M. et al. Beyond total mesorectal excision (TME): results of MRI-guided multivisceral resections in T4 rectal carcinoma and local recurrence. Cancers (Basel) 2023; 15 (22) 5328
• 94 PelvEx Collaborative. Surgical and survival outcomes following pelvic exenteration for locally advanced primary rectal cancer: results from an international collaboration. Ann Surg 2019; 269 (02) 315-321
• 95 PelvEx Collaborative. Factors affecting outcomes following pelvic exenteration for locally recurrent rectal cancer. Br J Surg 2018; 105 (06) 650-657
• 96 Sahni VA, Silveira PC, Sainani NI, Khorasani R. Impact of a structured report template on the quality of MRI reports for rectal cancer staging. AJR Am J Roentgenol 2015; 205 (03) 584-588
• 97 Nörenberg D, Sommer WH, Thasler W. et al. Structured reporting of rectal magnetic resonance imaging in suspected primary rectal cancer: potential benefits for surgical planning and interdisciplinary communication. Invest Radiol 2017; 52 (04) 232-239
• 98 Tersteeg JJC, Gobardhan PD, Crolla RMPH. et al. Improving the quality of MRI reports of preoperative patients with rectal cancer: effect of national guidelines and structured reporting. AJR Am J Roentgenol 2018; 210 (06) 1240-1244
• 99 Brown PJ, Rossington H, Taylor J. et al; YCR BCIP Study Group. Standardised reports with a template format are superior to free text reports: the case for rectal cancer reporting in clinical practice. Eur Radiol 2019; 29 (09) 5121-5128
• 100 Gollub MJ, Arya S, Beets-Tan RG. et al. Use of magnetic resonance imaging in rectal cancer patients: Society of Abdominal Radiology (SAR) rectal cancer disease-focused panel (DFP) recommendations 2017. Abdom Radiol (NY) 2018; 43 (11) 2893-2902
• 101 Kassam Z, Lang R, Arya S. et al. Update to the structured MRI report for primary staging of rectal cancer: perspective from the SAR disease focused panel on rectal and anal cancer. Abdom Radiol (NY) 2022; 47 (10) 3364-3374
• 102 Nougaret S, Rousset P, Gormly K. et al. Structured and shared MRI staging lexicon and report of rectal cancer: a consensus proposal by the French Radiology Group (GRERCAR) and Surgical Group (GRECCAR) for rectal cancer. Diagn Interv Imaging 2022; 103 (03) 127-141